Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
Besides Arg overexpression our data revealed
2023-08-09
Besides Arg2 overexpression, our data revealed that AGEs could decrease eNOS mRNA levels, which is considered a significant cause for attenuated NO production and vasodilation. It was found recently that AGEs significantly reduce eNOS expression levels and NO bioavailability in human carotid artery
-
In summary present evidence suggests that
2023-08-09
In summary, present evidence suggests that antimicrobial therapy for intra-abdominal sepsis can be shortened in patients exhibiting a clinical response to treatment. Hence, clinicians should use the resolution of clinical signs of infection as a guide to determine when during the 4–7-day window anti
-
Several studies have explored the relationship between denta
2023-08-09
Several studies have explored the relationship between dental implants and MRONJ development. López-Cedrún JL et al. [13] reported that BRONJ developed after implant treatment in nine patients who were taking bisphosphonates orally. The mean interval between the initiation of treatment and the onset
-
Nanoparticles are submicrometric systems smaller than
2023-08-08
Nanoparticles are submicrometric systems smaller than 1000 nm which high surface area and composite materials may allow their greater interaction with biological membranes and control of the drug release. These features are directly associated with the efficacy of treatment and the presence of adver
-
br Conclusions and perspectives In view of
2023-08-08
Conclusions and perspectives In view of the evidences supporting that NVP-BEP800 MAS receptors mediate the effects of AT1 antagonists (Iwai et al., 2012, Ohshima et al., 2014, Pernomian et al., 2015, Schuchard et al., 2015), the prime targets from the perspectives on future directions in the inte
-
The excellent safety profile of solanezumab and encouraging
2023-08-08
The excellent safety profile of solanezumab and encouraging trends in the exploratory analyses in mild AD led to its inclusion in two secondary prevention trials, which are continuing in the hope that earlier intervention may yield more substantial benefit. The A4 study (NCT02008357) started in Febr
-
The increased occurrence of ARIA E in APOE
2023-08-08
The increased occurrence of ARIA-E in APOE ε4 carriers in phase 2 studies resulted in separate protocols for carriers and noncarriers in the subsequent phase 3 studies. Two 18-month trials comprising 1121 carriers and 1331 noncarriers with mild to moderate AD tested doses of bapineuzumab that varied
-
Introduction Lipoxygenases LOXs are key enzymes that catalyz
2023-08-08
Introduction Lipoxygenases (LOXs) are key enzymes that catalyze the polyunsaturated fatty acids (PUFAs) such as arachidic 2143 (AA), linoleic acid (LA) and others unsaturated fatty acids (Brash, 1999). LOXs are expressed in immune, neural, epithelial, tumor cells and other cells (Claesson, 2009). B
-
br Materials and methods br Results br
2023-08-08
Materials and methods Results Discussion Knowledge of the molecular basis of an inherited genetic disease is crucial for understanding the disease pathology and, ultimately, for therapeutic design. Several recent reports have stressed the need for physical characterization of disease-associ
-
The fact that Yoda can activate Piezo in
2023-08-08
The fact that Yoda1 can activate Piezo1 in the absence of other cellular components other than a cell membrane [2], suggests that it may directly interact with and activate Piezo1. However, this does not preclude Yoda1 from interacting and activating non-Piezo channels, particularly in endothelial c
-
br Experimental procedures br Results br Discussion
2023-08-07
Experimental procedures Results Discussion Although previous studies have indicated that astrocyte aromatase plays a role in nociceptive processes (O'Brien et al., 2015, Smeester et al., 2016), the mechanisms responsible for the regulation of aromatase and its involvement in nociception rem
-
Currently NSAIDs which achieve antineoplastic actions mainly
2023-08-07
Currently, NSAIDs which achieve antineoplastic actions mainly through apoptosis are emerging choice in chemotherapy. Their antineoplastic effects were demonstrated before in tumor-bearing models [5], [6], [7]. Through in vitro cell models, we identified an indomethacin-activation of ceramide/PP2A/Ak
-
Introduction Plant pathogenic fungi are major pathogens in a
2023-08-07
Introduction Plant pathogenic fungi are major pathogens in agricultural diseases and the cause of large crop losses worldwide. There are many kinds of plant pathogenic fungi, with various modes of action. For example, Botrytis cinerea (B. cinerea) is the disease pathogen in the economically importa
-
br HIF Signaling in AA Therapy Resistance An
2023-08-07
HIF-α Signaling in AA Therapy Resistance An important result emerging from Phase 3 clinical trials testing AA therapies is improvement of progression-free survival (PFS) that is not accompanied by enhanced overall survival (OS) [26]. This dichotomy has been attributed to mechanisms of acquired re
-
Overexpression of AR can lead to sorbitol accumulation
2023-08-07
Overexpression of AR can lead to sorbitol accumulation, leading to diabetic complications (Ransohoff and Cardona, 2010). Therefore, AR is an important enzyme in the growth and development of organisms. With the aim of inhibiting the activity of AR in diabetic patients, screening for inhibitors and i
15717 records 279/1048 page Previous Next First page 上5页 276277278279280 下5页 Last page